NUVATION BIO
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New York, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1500 Broadway Ste 1401, New York City, N...Phone Number
(332) 208-6102Website
www.nuvationbio.comRevenue
$143 MillionStock Symbol
NUVBIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
1
2
1
1
1
About NUVATION BIO
Nuvation Bio is a global biopharmaceutical company focused on treating patients with the most difficult-to-treat cancers for which conventional therapies have failed. Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates.Explore more
NUVATION BIO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NUVATION BIO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if NUVATION BIO has recently received funding, and reach out quickly before it becomes old news!
Check out if NUVATION BIO is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at NUVATION BIO
Funding: Get notified immidiatlly once NUVATION BIO has new funding data
Product Launch: Get notified when NUVATION BIO launches new products
Click to see if NUVATION BIO had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
NUVATION BIO, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on NUVATION BIO recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to NUVATION BIO
Compare insights from companies similar to NUVATION BIO, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NUVATION BIO is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NUVATION BIO is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NUVATION BIO.
NUVATION BIO financials insights
Gather financial insights about NUVATION BIO, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$275M
2025
Other Financing Round
$250M
NUVATION BIO Tech Stack
A closer look at the technologies used by NUVATION BIO
See more technologies
Most Recent Scoops
Project
NUVATION BIO has announced that IBTROZI demonstrated that 88% of patients showed improvement or stability across multiple health-related quality of life outcomes in the TRUST-II study presented at ASCO, making IBTROZI the only ROS1 drug to show improvement in patient cognition and reporting symptom relief including reduced cough and shortness of breath prior to confirmed radiographic response.
Medical Research, Pharmaceuticals
Partnership
NUVATION BIO has announced that its partnership with Ionis is progressing, with Ionis having selected four targets in wave one TTR, AGT, APOC3, and one undisclosed target with a 50/50 co-development and co-promote option available to Metagenomi Therapeutics upon Ionis declaring a development candidate.
Partnership
Project
NUVATION BIO has announced that the TRUST-I and TRUST-II studies for IBTROZI did not exclude patients with concomitant driver mutations, making the 90% response rate and 50-month duration of response data applicable to a broad, real-world patient population including the most difficult-to-treat cases.
Medical Research, Pharmaceuticals
Open Position
Open Position
NUVATION BIO News & Media
Is Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?
In late June 2026, Nuvation Bio announced that partner Eisai’s Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non-small cell lung cancer was validated by the U.K. MHRA under the International Recognition Procedure, adding to an already validated application with the European Medicines Agency and planned filings in Canada and other regions. This regulatory momentum highlights how taletrectinib, already approved as IBTROZI in the U.S., Japan and China, could...Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?
This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE. A Marketing Authorisation Application with the European Medicines Agency is also under regulatory review for approval NEW YORK, June 29, 2026 /PRNewswire/ -- Nuvation Bio (NYSE: NUVB), a global oncology company...Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the "Offering") of $250.0 million aggregate principal...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NUVATION BIO
Sign Up For FreeTo access detailed company insights
Nuvation Bio is a global biopharmaceutical company focused on treating patients with the most difficult-to-treat cancers for which conventional therapies have failed. Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates.... Read More
